28 September 2017 - - San Diego, California-based non-prescription medicine and consumer care products company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has reported the availability of the full label for its nasal drug FlutiCare for allergy symptom relief on the US Food and Drug Administration's public drug disclosure database, DailyMed, the company said.
DailyMed is the on-line database on which all new drugs are described that provides information to the public on its ingredients and usage.
FlutiCare, similar to Flonase and ClariSpray, is approved by the FDA for over-the-counter (OTC) use for "Allergy Symptom Relief" and is indicated to "Temporarily relieve these symptoms of hay fever or other upper respiratory allergies, including nasal congestion, runny nose, sneezing, itchy nose, and itchy, watery eyes."
Innovus Pharma is engaged in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality, and respiratory diseases.
The company delivers packaged health solutions through its directly marketed OTC medicines and consumer and health products, commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through on-line channels, retailers, and wholesalers.